| Literature DB >> 28211154 |
D Di Bona1, A Aiello2, C Colomba3, M Bilancia4, G Accardi2, R Rubino3, L Giannitrapani5, A Tuttolomondo5, A Cascio3, M F Caiaffa6, S Rizzo7, G Di Lorenzo5, G Candore2,7, G Duro8, L Macchia1, G Montalto5, C Caruso2,7.
Abstract
Killer immunoglobulin-like receptors (KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens (HLA). KIR and HLA loci are highly polymorphic, and certain HLA-KIR combinations have been found to protect against viral infections. In this study, we analysed whether the KIR/HLA repertoire may influence the course of hepatitis B virus (HBV) infection. Fifty-seven subjects with chronic hepatitis B (CHB), 44 subjects with resolved HBV infection and 60 healthy uninfected controls (HC) were genotyped for KIR and their HLA ligands. The frequency of the HLA-A-Bw4 ligand group was higher in CHB (58%) than subjects with resolved infection (23%) (crude OR, 4.67; P<.001) and HC (10%) (crude OR, 12.38; P<.001). Similar results were obtained for the HLA-C2 ligand group, more frequent in CHB (84%), than subjects with resolved infection (70%) (crude OR, 2.24; P<.10) and HC (60%) (crude OR, 3.56; P<.01). Conversely, the frequency of KIR2DL3 was lower in CHB (81%) than in subjects with resolved infection (98%) (crude OR, 0.10; P<.05). These results suggest a detrimental role of HLA-A-Bw4 and HLA-C2 groups, which are associated with the development of CHB, and a protective role of KIR2DL3. A stepwise variable selection procedure, based on multiple logistic regression analysis, identified these three predictive variables as the most relevant, featuring high specificity (90.9%) and positive predictive value (87.5%) for the development of CHB. Our results suggest that a combination of KIR/HLA gene/alleles is able to predict the outcome of HBV infection.Entities:
Keywords: zzm321990HLAzzm321990; zzm321990killer cell immunoglobulin-like receptorzzm321990; zzm321990natural killerzzm321990; hepatitis B virus
Mesh:
Substances:
Year: 2017 PMID: 28211154 DOI: 10.1111/jvh.12698
Source DB: PubMed Journal: J Viral Hepat ISSN: 1352-0504 Impact factor: 3.728